Intuitive Surgical, Inc. (ISRG) Up 8.3% — Is This the Window to Get Long?
Intuitive Surgical, Inc. (ISRG) is delivering one of its strongest sessions in more than a year. On Wednesday, the stock is currently trading at $477.20 on the NASDAQ, a $36.45 gain over the prior close of $440.75. ISRG is on pace for its largest percentage increase since October 2025. Even after this jump, ISRG remains roughly 21.0% below its 52-week high of $603.88, set on January 7, 2026. That gap leaves meaningful room for recovery in a company whose fundamentals have held firm while the share price retreated.
Volume stands at about 1.27 million shares with the session still underway, compared with a 90-day average of roughly 2.81 million. The advance is coming on measured turnover so far, with buyers lifting the stock steadily rather than through a single burst of activity.
Why Intuitive Surgical, Inc. Price is Moving Higher
The lead driver is a broad Health Care rally that followed Democrats' congressional sweep. On November 4, the Health Care Select Sector SPDR (XLV) rose 2.6% in premarket trading and the iShares Biotechnology ETF (IBB) gained 2.9%. Contemporaneous coverage tied the optimism to the prospect of Medicaid and Affordable Care Act subsidy relief. The most direct policy beneficiaries surged, with Centene (CNC) up 4.6%, Molina Healthcare (MOH) up 6.6%, and HCA up 6.5%. That wave of sector buying spread into medical technology, where Stryker Corporation (SYK) is up 7.48% and Abbott Laboratories (ABT) has gained 4.76%.
ISRG is outpacing even those gains because the sector tailwind landed on a high-growth name trading well below its January peak, and the move gathered force through the morning. The stock was up 7.25% at $472.72 by 10:08 a.m. ET and later touched $476.70, up 8.16%. It has since pushed beyond that level to $477.20.
The fundamental case behind the rebound is strong. On October 20, Intuitive reported Q3 adjusted EPS of $3.00, well ahead of the $2.65 consensus and up 25% from $2.40 a year earlier. Revenue reached $3.05 billion against a $2.91 billion estimate, a 22% year-over-year increase. GAAP EPS declined to $1.49 from $1.95, largely because of a $450 million antitrust-settlement charge. That is a one-time item and does not affect the operating trend. Management also narrowed its 2026 da Vinci procedure-growth outlook to 14% to 15%, from the prior 13.5% to 15.5% range, which tightens the band around the midpoint and signals confidence in demand through year-end. With that growth profile intact, today's sector-wide bid gave investors a clear reason to step back into the name.
What is the Intuitive Surgical, Inc. Rating - Should I Buy?
Weiss Ratings assigns ISRG a C rating. Current recommendation is Hold. That rating reflects a business with top-tier fundamentals whose stock has not yet delivered for shareholders, and today's rally is starting to narrow that gap.
The operating side of the scorecard is exceptional. Intuitive is rated Excellent on the Growth Index, Efficiency Index, and Solvency Index, a rare combination for a company of this size. The Growth Index rating reflects 21.70% revenue growth, a pace more typical of an emerging medtech player than a $152.78 billion incumbent. The 22% top-line increase in the third quarter shows that momentum is not slowing. A 25.54% profit margin supports the Excellent Efficiency rating, and it shows how much each procedure contributes once a da Vinci system is installed and instruments and accessories begin flowing through. ROE of 17.93% is solid rather than spectacular. It reflects a company that funds its expansion largely from its own cash generation instead of borrowed money, and that same conservative capital structure underpins the Excellent rating on the Solvency Index. The balance sheet can absorb a $450 million legal charge without disrupting the business.
Where the picture becomes more nuanced is in how the stock itself has behaved. ISRG is rated Fair on the Total Return Index, which reflects a share price still about 21% below its January high despite consistently strong operating results. The Weak Volatility Index reflects price swings like today's 8.27% jump, which was triggered by a sector-wide policy rally rather than company news. A forward P/E of 53.35 adds to that sensitivity, because a premium valuation tends to amplify the stock's response to shifts in Health Care sentiment in either direction. These two dimensions keep the overall rating at C. Investors who believe the growth story will eventually be reflected in the share price may see them as the source of today's opportunity.
Within the Health Care sector, Intuitive Surgical is on par with Stryker Corporation (SYK, C), Abbott Laboratories (ABT, C), and UnitedHealth Group Incorporated (UNH, C). It trails only CVS Health Corporation (CVS, C+) among the peers cited here. Few of those companies can match Intuitive's combination of three Excellent fundamental indices.
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. (ISRG) is a Health Care company and the pioneer of robotic-assisted minimally invasive surgery. Founded in 1995 and headquartered in Sunnyvale, California, the company develops, manufactures, and markets the da Vinci surgical system. The platform lets surgeons perform complex procedures through small incisions with enhanced 3D visualization, wristed instrumentation, and precise control. The da Vinci family includes the multiport da Vinci Xi, the next-generation da Vinci 5, and the da Vinci SP single-port system, and it is used across general surgery, urology, gynecology, thoracic, and colorectal procedures. The company also offers the Ion endoluminal system, a robotic platform for minimally invasive biopsy deep in the lung that extends Intuitive's reach into diagnostic and early cancer detection.
The business model is built on recurring revenue. Each installed system generates ongoing sales of instruments and accessories, including EndoWrist instruments, stapling products, and SynchroSeal vessel-sealing tools, along with service contracts, system leasing, and training programs. As a result, the installed base of thousands of systems worldwide feeds revenue with every procedure performed. Procedure volume, which management expects to grow 14% to 15% in 2026, is the core engine of the company's results.
Intuitive's competitive advantages are deep and difficult to replicate. More than two decades of clinical data, a vast patent portfolio, and a large population of surgeons trained on da Vinci create high switching costs for hospitals. Its integrated ecosystem of hardware, software, instruments, analytics, and education strengthens its position as the established leader in surgical robotics, even as larger medical device companies invest to compete.
Investor Outlook
Intuitive Surgical, Inc. (ISRG) carries a Weiss Rating of C (Hold). Today's sector-fueled rally puts its underlying 22% revenue growth and Excellent fundamental indices back in focus, with the stock still about 21% below its January high. Investors should watch whether procedure growth holds within the 14% to 15% guidance range through year-end, and whether the policy-driven Health Care rally carries momentum into the company's next quarterly report. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--